Kategoria: Badania

SOM Biotech kończy proces rekrutacji w badaniu fazy IIb leczenia pląsawicy w chorobie Huntingtona

SOM Biotech, a clinical-stage drug discovery and development company based on a unique proprietary Artificial Intelligence platform (SOMAIPRO®), is pleased to announce that the recruitment of the Phase IIb clinical […]

Prilenia planuje złożyć wniosek o pozwolenie na dopuszczenie do obrotu w UE dla pridopidyny w chorobie Huntingtona

Prilenia announced today that they plan to submit a Marketing Authorization Application in the EU for the use of Pridopidine in the treatment of Huntington’s Disease. According to Dr. Michael […]

Przełom stanowi nową nadzieję dla pacjentów z HD

Scientists from the Weizmann Institute in Israel have published the results of an animal study which holds tremendous promise for the treatment of Huntington’s Disease.  They have discovered that two […]

uniQure ogłasza aktualizację badań klinicznych fazy I/II terapii genowej AMT-130 w leczeniu choroby Huntingtona

~ Patients treated with AMT-130 continue to show evidence of preserved neurological function with potential dose-dependent clinical benefits relative to an inclusion criteria-matched natural history of the disease ~ ~ Mean […]

PTC Therapeutics udostępnia pozytywne wstępne dane z badania klinicznego PIVOT-HD u pacjentów z chorobą Huntingtona

June 21, 2023 PDF Version – Dose-dependent lowering of blood Huntingtin (HTT) protein levels at 12 weeks –– Favorable tolerability profile with no treatment-related serious adverse events or NfL spikes –  – Conference […]

uniQure ogłasza aktualizację amerykańskich badań klinicznych fazy I/II terapii genowej AMT-130 w leczeniu choroby Huntingtona

~ AMT-130 continues to be generally well-tolerated across both dose cohorts ~ ~ Patients treated with AMT-130 show preserved function compared to baseline and clinical benefits relative to natural history […]

PRILENIA OGŁASZA WYNIKI BADANIA PROOF-HD: OBIECUJĄCE, ALE MIESZANE WYNIKI!

Today, April 25th, Prilenia announced results from the PROOF-HD clinical trial for Huntington’s Disease. Some of the participants showed significant benefits from the Pridopidine drug, while others did not benefit at all.  This […]

Prilenia uzyskała ostatnią wizytę pacjenta w badaniu klinicznym fazy 3 PROOF-HD dla choroby Huntingtona

PROOF-HD is the only late-stage study in Huntington’s disease targeting clinical progression; topline results expected in early Q2 2023 NAARDEN, Netherlands and WALTHAM, Mass., 28 March 2023 – Prilenia Therapeutics B.V., a […]

Aktualizacja informacji o badaniu GENERATION HD2 przez firmy Roche i Genentech

Roche/ Genentech announce that Phase II GENERATION HD2 study is now open. This is great news for the international community since it is planned to run in 15 countries (Argentina, […]

Novartis kończy badanie VIBRANT-HD

Novartis shared today the difficult news that they are stopping the VIBRANT-HD study of Branaplam, after some participants devoloping side effects. Read the full Novartis letter Even if this news […]